ID   ERBB3_HUMAN             Reviewed;        1342 AA.
AC   P21860;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1991, sequence version 1.
DT   02-NOV-2010, entry version 129.
DE   RecName: Full=Receptor tyrosine-protein kinase erbB-3;
DE            EC=2.7.10.1;
DE   AltName: Full=Proto-oncogene-like protein c-ErbB-3;
DE   AltName: Full=Tyrosine kinase-type cell surface receptor HER3;
DE   Flags: Precursor;
GN   Name=ERBB3; Synonyms=HER3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   MEDLINE=90083234; PubMed=2687875; DOI=10.1073/pnas.86.23.9193;
RA   Kraus M.H., Issing W., Miki T., Popescu N.C., Aaronson S.A.;
RT   "Isolation and characterization of ERBB3, a third member of the
RT   ERBB/epidermal growth factor receptor family: evidence for
RT   overexpression in a subset of human mammary tumors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:9193-9197(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   MEDLINE=90311312; PubMed=2164210; DOI=10.1073/pnas.87.13.4905;
RA   Plowman G.D., Whitney G.S., Neubauer M.G., Green J.M., McDonald V.L.,
RA   Todaro G.J., Shoyab M.;
RT   "Molecular cloning and expression of an additional epidermal growth
RT   factor receptor-related gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:4905-4909(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   MEDLINE=93282822; PubMed=7685162; DOI=10.1006/bbrc.1993.1542;
RA   Katoh M., Yazaki Y., Sugimura T., Terada M.;
RT   "c-erbB3 gene encodes secreted as well as transmembrane receptor
RT   tyrosine kinase.";
RL   Biochem. Biophys. Res. Commun. 192:1189-1197(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INTERACTION WITH PA2G4.
RX   PubMed=11325528; DOI=10.1016/S0303-7207(01)00387-2;
RA   Lessor T.J., Hamburger A.W.;
RT   "Regulation of the ErbB3 binding protein Ebp1 by protein kinase C.";
RL   Mol. Cell. Endocrinol. 175:185-191(2001).
RN   [6]
RP   INTERACTION WITH MUC1.
RX   PubMed=12939402;
RA   Li Y., Yu W.-H., Ren J., Chen W., Huang L., Kharbanda S., Loda M.,
RA   Kufe D.;
RT   "Heregulin targets gamma-catenin to the nucleolus by a mechanism
RT   dependent on the DF3/MUC1 oncoprotein.";
RL   Mol. Cancer Res. 1:765-775(2003).
RN   [7]
RP   INTERACTION WITH CSPG5, AND FUNCTION.
RX   PubMed=15358134; DOI=10.1016/j.bbrc.2004.07.066;
RA   Kinugasa Y., Ishiguro H., Tokita Y., Oohira A., Ohmoto H.,
RA   Higashiyama S.;
RT   "Neuroglycan C, a novel member of the neuregulin family.";
RL   Biochem. Biophys. Res. Commun. 321:1045-1049(2004).
RN   [8]
RP   INVOLVEMENT IN LCCS2.
RX   PubMed=17701904; DOI=10.1086/520770;
RA   Narkis G., Ofir R., Manor E., Landau D., Elbedour K., Birk O.S.;
RT   "Lethal congenital contractural syndrome type 2 (LCCS2) is caused by a
RT   mutation in ERBB3 (Her3), a modulator of the phosphatidylinositol-3-
RT   kinase/Akt pathway.";
RL   Am. J. Hum. Genet. 81:589-595(2007).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1328, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Mammary epithelium;
RX   PubMed=17389395; DOI=10.1073/pnas.0608638104;
RA   Wolf-Yadlin A., Hautaniemi S., Lauffenburger D.A., White F.M.;
RT   "Multiple reaction monitoring for robust quantitative proteomic
RT   analysis of cellular signaling networks.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:5860-5865(2007).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-686, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1328, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Mammary epithelium;
RX   PubMed=19534553; DOI=10.1021/pr900044c;
RA   Heibeck T.H., Ding S.-J., Opresko L.K., Zhao R., Schepmoes A.A.,
RA   Yang F., Tolmachev A.V., Monroe M.E., Camp D.G. II, Smith R.D.,
RA   Wiley H.S., Qian W.-J.;
RT   "An extensive survey of tyrosine phosphorylation revealing new sites
RT   in human mammary epithelial cells.";
RL   J. Proteome Res. 8:3852-3861(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-680, AND MASS
RP   SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 20-640, DISULFIDE BONDS, AND
RP   GLYCOSYLATION AT ASN-250; ASN-353; ASN-408; ASN-414; ASN-437; ASN-469;
RP   ASN-522 AND ASN-566.
RX   PubMed=12154198; DOI=10.1126/science.1074611;
RA   Cho H.S., Leahy D.J.;
RT   "Structure of the extracellular region of HER3 reveals an interdomain
RT   tether.";
RL   Science 297:1330-1333(2002).
RN   [14]
RP   VARIANTS [LARGE SCALE ANALYSIS] TYR-20; LEU-30; MET-104; ILE-204;
RP   TRP-683; LEU-717; THR-744; ARG-998; CYS-1119; HIS-1127; ILE-1177 AND
RP   LYS-1254.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Binds and is activated by neuregulins and NTAK.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- SUBUNIT: Heterodimer with each of the other ERBB receptors
CC       (Potential). Interacts with CSPG5, PA2G4 and MUC1.
CC   -!- INTERACTION:
CC       P00533:EGFR; NbExp=2; IntAct=EBI-720706, EBI-297353;
CC       P04626:ERBB2; NbExp=7; IntAct=EBI-720706, EBI-641062;
CC       Q15303:ERBB4; NbExp=3; IntAct=EBI-720706, EBI-80371;
CC       Q02297:NRG1; NbExp=1; IntAct=EBI-720706, EBI-2460704;
CC       Q9UQ80:PA2G4; NbExp=1; IntAct=EBI-720706, EBI-924893;
CC       P42336:PIK3CA; NbExp=1; IntAct=EBI-720706, EBI-2116585;
CC       P27986:PIK3R1; NbExp=17; IntAct=EBI-720706, EBI-79464;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type I
CC       membrane protein.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=long form;
CC         IsoId=P21860-1; Sequence=Displayed;
CC       Name=2; Synonyms=short form;
CC         IsoId=P21860-2; Sequence=VSP_002893, VSP_002894;
CC   -!- TISSUE SPECIFICITY: Epithelial tissues and brain.
CC   -!- DEVELOPMENTAL STAGE: Overexpressed in a subset of human mammary
CC       tumors.
CC   -!- DOMAIN: The cytoplasmic part of the receptor may interact with the
CC       SH2 or SH3 domains of many signal-transducing proteins.
CC   -!- PTM: Ligand-binding increases phosphorylation on tyrosine residues
CC       and promotes its association with the p85 subunit of
CC       phosphatidylinositol 3-kinase (By similarity).
CC   -!- DISEASE: Defects in ERBB3 are the cause of lethal congenital
CC       contracture syndrome type 2 (LCCS2) [MIM:607598]; also called
CC       Israeli Bedouin multiple contracture syndrome type A. LCCS2 is an
CC       autosomal recessive neurogenic form of a neonatally lethal
CC       arthrogryposis that is associated with atrophy of the anterior
CC       horn of the spinal cord. The LCCS2 syndrome is characterized by
CC       multiple joint contractures, anterior horn atrophy in the spinal
CC       cord, and a unique feature of a markedly distended urinary
CC       bladder. The phenotype suggests a spinal cord neuropathic
CC       etiology.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. EGF receptor subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M29366; AAA35790.1; -; mRNA.
DR   EMBL; M34309; AAA35979.1; -; mRNA.
DR   EMBL; S61953; AAB26935.1; -; mRNA.
DR   EMBL; BC082992; AAH82992.1; -; mRNA.
DR   IPI; IPI00219206; -.
DR   IPI; IPI00298285; -.
DR   PIR; A36223; A36223.
DR   PIR; JH0803; JH0803.
DR   RefSeq; NP_001005915.1; -.
DR   RefSeq; NP_001973.2; -.
DR   UniGene; Hs.118681; -.
DR   PDB; 1M6B; X-ray; 2.60 A; A/B=20-640.
DR   PDB; 3KEX; X-ray; 2.80 A; A/B=698-1019.
DR   PDB; 3LMG; X-ray; 2.80 A; A/B=684-1020.
DR   PDBsum; 1M6B; -.
DR   PDBsum; 3KEX; -.
DR   PDBsum; 3LMG; -.
DR   ProteinModelPortal; P21860; -.
DR   SMR; P21860; 667-718, 697-979.
DR   DIP; DIP-36441N; -.
DR   IntAct; P21860; 42.
DR   MINT; MINT-158484; -.
DR   STRING; P21860; -.
DR   PhosphoSite; P21860; -.
DR   PRIDE; P21860; -.
DR   Ensembl; ENST00000267101; ENSP00000267101; ENSG00000065361.
DR   GeneID; 2065; -.
DR   KEGG; hsa:2065; -.
DR   UCSC; uc001sjg.1; human.
DR   UCSC; uc001sjh.1; human.
DR   CTD; 2065; -.
DR   GeneCards; GC12P056473; -.
DR   H-InvDB; HIX0010715; -.
DR   HGNC; HGNC:3431; ERBB3.
DR   HPA; CAB025331; -.
DR   MIM; 190151; gene.
DR   MIM; 607598; phenotype.
DR   Orphanet; 137776; Lethal congenital contracture syndrome type 2.
DR   PharmGKB; PA27846; -.
DR   eggNOG; prNOG10003; -.
DR   HOGENOM; HBG445128; -.
DR   HOVERGEN; HBG000490; -.
DR   InParanoid; P21860; -.
DR   OMA; GTTPDED; -.
DR   OrthoDB; EOG9KPWX4; -.
DR   PhylomeDB; P21860; -.
DR   BRENDA; 2.7.10.1; 247.
DR   Pathway_Interaction_DB; a6b1_a6b4_integrin_pathway; a6b1 and a6b4 Integrin signaling.
DR   NextBio; 8391; -.
DR   ArrayExpress; P21860; -.
DR   Bgee; P21860; -.
DR   CleanEx; HS_ERBB3; -.
DR   Genevestigator; P21860; -.
DR   GermOnline; ENSG00000065361; Homo sapiens.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0005887; C:integral to plasma membrane; TAS:ProtInc.
DR   GO; GO:0043235; C:receptor complex; ISS:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019838; F:growth factor binding; IPI:BHF-UCL.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; NAS:BHF-UCL.
DR   GO; GO:0030296; F:protein tyrosine kinase activator activity; IDA:BHF-UCL.
DR   GO; GO:0004716; F:receptor signaling protein tyrosine kinase ...; IEA:InterPro.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kin...; IEA:EC.
DR   GO; GO:0021545; P:cranial nerve development; ISS:BHF-UCL.
DR   GO; GO:0007507; P:heart development; ISS:BHF-UCL.
DR   GO; GO:0007162; P:negative regulation of cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0043524; P:negative regulation of neuron apoptosis; ISS:BHF-UCL.
DR   GO; GO:0051048; P:negative regulation of secretion; IDA:BHF-UCL.
DR   GO; GO:0009968; P:negative regulation of signal transduction; IDA:BHF-UCL.
DR   GO; GO:0051402; P:neuron apoptosis; IMP:BHF-UCL.
DR   GO; GO:0014065; P:phosphoinositide 3-kinase cascade; IDA:BHF-UCL.
DR   GO; GO:0014068; P:positive regulation of phosphoinositide 3-k...; TAS:BHF-UCL.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; IEA:InterPro.
DR   GO; GO:0042127; P:regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0014037; P:Schwann cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kin...; ISS:BHF-UCL.
DR   GO; GO:0042060; P:wound healing; NAS:BHF-UCL.
DR   InterPro; IPR000494; EGF_rcpt_L.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR009030; Growth_fac_rcpt.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR016245; Tyr_kinase_EGF/ERB/XmrK_rcpt.
DR   InterPro; IPR020692; Tyr_kinase_rcpt_ErbB3.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   PANTHER; PTHR23256:SF25; Tyr_kinase_rcpt_erbB3; 1.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000619; TyrPK_EGF-R; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00261; FU; 5.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF57184; Grow_fac_recept; 2.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; FALSE_NEG.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; FALSE_NEG.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Complete proteome; Disulfide bond; Glycoprotein; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Receptor; Secreted;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1     19       Potential.
FT   CHAIN        20   1342       Receptor tyrosine-protein kinase erbB-3.
FT                                /FTId=PRO_0000016672.
FT   TOPO_DOM     20    643       Extracellular (Potential).
FT   TRANSMEM    644    664       Helical; (Potential).
FT   TOPO_DOM    665   1342       Cytoplasmic (Potential).
FT   DOMAIN      709    966       Protein kinase.
FT   NP_BIND     715    723       ATP (By similarity).
FT   ACT_SITE    834    834       Proton acceptor (By similarity).
FT   BINDING     742    742       ATP (By similarity).
FT   MOD_RES     680    680       Phosphotyrosine.
FT   MOD_RES     686    686       Phosphoserine.
FT   MOD_RES    1328   1328       Phosphotyrosine.
FT   CARBOHYD    126    126       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    250    250       N-linked (GlcNAc...).
FT   CARBOHYD    353    353       N-linked (GlcNAc...).
FT   CARBOHYD    408    408       N-linked (GlcNAc...).
FT   CARBOHYD    414    414       N-linked (GlcNAc...).
FT   CARBOHYD    437    437       N-linked (GlcNAc...).
FT   CARBOHYD    469    469       N-linked (GlcNAc...).
FT   CARBOHYD    522    522       N-linked (GlcNAc...).
FT   CARBOHYD    566    566       N-linked (GlcNAc...).
FT   CARBOHYD    616    616       N-linked (GlcNAc...) (Potential).
FT   DISULFID     29     56
FT   DISULFID    156    183
FT   DISULFID    186    194
FT   DISULFID    190    202
FT   DISULFID    210    218
FT   DISULFID    214    226
FT   DISULFID    227    235
FT   DISULFID    231    243
FT   DISULFID    246    255
FT   DISULFID    259    286
FT   DISULFID    290    301
FT   DISULFID    305    320
FT   DISULFID    323    327
FT   DISULFID    500    509
FT   DISULFID    504    517
FT   DISULFID    520    529
FT   DISULFID    533    549
FT   DISULFID    552    565
FT   DISULFID    556    573
FT   DISULFID    576    585
FT   DISULFID    589    610       By similarity.
FT   DISULFID    613    621       By similarity.
FT   DISULFID    617    629       By similarity.
FT   VAR_SEQ     141    183       EILSGGVYIEKNDKLCHMDTIDWRDIVRDRDAEIVVKDNGR
FT                                SC -> GQFPMVPSGLTPQPAQDWYLLDDDPRLLTLSASSK
FT                                VPVTLAAV (in isoform 2).
FT                                /FTId=VSP_002893.
FT   VAR_SEQ     184   1342       Missing (in isoform 2).
FT                                /FTId=VSP_002894.
FT   VARIANT      20     20       S -> Y (in dbSNP:rs34379766).
FT                                /FTId=VAR_042101.
FT   VARIANT      30     30       P -> L (in dbSNP:rs56017157).
FT                                /FTId=VAR_042102.
FT   VARIANT     104    104       V -> M (in an ovarian mucinous carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_042103.
FT   VARIANT     204    204       T -> I (in dbSNP:rs56107455).
FT                                /FTId=VAR_042104.
FT   VARIANT     385    385       N -> S (in dbSNP:rs12320176).
FT                                /FTId=VAR_049710.
FT   VARIANT     683    683       R -> W (in dbSNP:rs56387488).
FT                                /FTId=VAR_042105.
FT   VARIANT     717    717       S -> L (in dbSNP:rs35961836).
FT                                /FTId=VAR_042106.
FT   VARIANT     744    744       I -> T (in dbSNP:rs55787439).
FT                                /FTId=VAR_042107.
FT   VARIANT     998    998       K -> R (in dbSNP:rs56259600).
FT                                /FTId=VAR_042108.
FT   VARIANT    1119   1119       S -> C (in dbSNP:rs773123).
FT                                /FTId=VAR_042109.
FT   VARIANT    1127   1127       R -> H (in dbSNP:rs2271188).
FT                                /FTId=VAR_042110.
FT   VARIANT    1177   1177       L -> I (in dbSNP:rs55699040).
FT                                /FTId=VAR_042111.
FT   VARIANT    1254   1254       T -> K (in dbSNP:rs55709407).
FT                                /FTId=VAR_042112.
FT   VARIANT    1271   1271       G -> S (in dbSNP:rs11171743).
FT                                /FTId=VAR_049711.
FT   CONFLICT    560    560       E -> G (in Ref. 2; AAA35979).
FT   CONFLICT   1064   1064       E -> G (in Ref. 2; AAA35979).
FT   STRAND       58     61
FT   STRAND       63     67
FT   HELIX        75     79
FT   STRAND       82     85
FT   STRAND       87     91
FT   STRAND       95     98
FT   TURN        112    114
FT   STRAND      115    120
FT   STRAND      133    135
FT   STRAND      146    150
FT   TURN        158    160
FT   HELIX       163    166
FT   STRAND      174    178
FT   STRAND      194    198
FT   STRAND      214    216
FT   STRAND      218    222
FT   STRAND      231    233
FT   STRAND      235    239
FT   HELIX       240    242
FT   STRAND      243    251
FT   STRAND      254    258
FT   STRAND      262    265
FT   TURN        267    269
FT   STRAND      270    274
FT   STRAND      280    282
FT   STRAND      285    289
FT   STRAND      295    297
FT   STRAND      300    304
FT   STRAND      309    314
FT   STRAND      317    322
FT   STRAND      330    332
FT   TURN        345    347
FT   HELIX       348    351
FT   STRAND      356    363
FT   HELIX       365    369
FT   TURN        372    375
FT   HELIX       381    389
FT   STRAND      392    395
FT   STRAND      397    400
FT   HELIX       410    412
FT   STRAND      425    433
FT   STRAND      451    457
FT   HELIX       470    473
FT   STRAND      482    488
FT   HELIX       490    493
FT   TURN        494    497
FT   STRAND      509    513
FT   HELIX       514    516
FT   STRAND      517    527
FT   STRAND      529    531
FT   STRAND      534    536
FT   STRAND      538    540
FT   STRAND      542    545
FT   STRAND      548    551
FT   STRAND      564    570
FT   STRAND      573    581
FT   STRAND      584    588
FT   STRAND      600    604
FT   STRAND      608    612
FT   STRAND      622    625
SQ   SEQUENCE   1342 AA;  148098 MW;  7201E7F66CA374BD CRC64;
     MRANDALQVL GLLFSLARGS EVGNSQAVCP GTLNGLSVTG DAENQYQTLY KLYERCEVVM
     GNLEIVLTGH NADLSFLQWI REVTGYVLVA MNEFSTLPLP NLRVVRGTQV YDGKFAIFVM
     LNYNTNSSHA LRQLRLTQLT EILSGGVYIE KNDKLCHMDT IDWRDIVRDR DAEIVVKDNG
     RSCPPCHEVC KGRCWGPGSE DCQTLTKTIC APQCNGHCFG PNPNQCCHDE CAGGCSGPQD
     TDCFACRHFN DSGACVPRCP QPLVYNKLTF QLEPNPHTKY QYGGVCVASC PHNFVVDQTS
     CVRACPPDKM EVDKNGLKMC EPCGGLCPKA CEGTGSGSRF QTVDSSNIDG FVNCTKILGN
     LDFLITGLNG DPWHKIPALD PEKLNVFRTV REITGYLNIQ SWPPHMHNFS VFSNLTTIGG
     RSLYNRGFSL LIMKNLNVTS LGFRSLKEIS AGRIYISANR QLCYHHSLNW TKVLRGPTEE
     RLDIKHNRPR RDCVAEGKVC DPLCSSGGCW GPGPGQCLSC RNYSRGGVCV THCNFLNGEP
     REFAHEAECF SCHPECQPME GTATCNGSGS DTCAQCAHFR DGPHCVSSCP HGVLGAKGPI
     YKYPDVQNEC RPCHENCTQG CKGPELQDCL GQTLVLIGKT HLTMALTVIA GLVVIFMMLG
     GTFLYWRGRR IQNKRAMRRY LERGESIEPL DPSEKANKVL ARIFKETELR KLKVLGSGVF
     GTVHKGVWIP EGESIKIPVC IKVIEDKSGR QSFQAVTDHM LAIGSLDHAH IVRLLGLCPG
     SSLQLVTQYL PLGSLLDHVR QHRGALGPQL LLNWGVQIAK GMYYLEEHGM VHRNLAARNV
     LLKSPSQVQV ADFGVADLLP PDDKQLLYSE AKTPIKWMAL ESIHFGKYTH QSDVWSYGVT
     VWELMTFGAE PYAGLRLAEV PDLLEKGERL AQPQICTIDV YMVMVKCWMI DENIRPTFKE
     LANEFTRMAR DPPRYLVIKR ESGPGIAPGP EPHGLTNKKL EEVELEPELD LDLDLEAEED
     NLATTTLGSA LSLPVGTLNR PRGSQSLLSP SSGYMPMNQG NLGESCQESA VSGSSERCPR
     PVSLHPMPRG CLASESSEGH VTGSEAELQE KVSMCRSRSR SRSPRPRGDS AYHSQRHSLL
     TPVTPLSPPG LEEEDVNGYV MPDTHLKGTP SSREGTLSSV GLSSVLGTEE EDEDEEYEYM
     NRRRRHSPPH PPRPSSLEEL GYEYMDVGSD LSASLGSTQS CPLHPVPIMP TAGTTPDEDY
     EYMNRQRDGG GPGGDYAAMG ACPASEQGYE EMRAFQGPGH QAPHVHYARL KTLRSLEATD
     SAFDNPDYWH SRLFPKANAQ RT
//
